1, Newborns of HBsAg-positive mothers should be given HBIG as early as possible (preferably within 12 h after birth) at a dose of ≥100 IU, along with 10 μg of recombinant yeast hepatitis B vaccine at different sites, and the second and third doses of hepatitis B vaccine at 1 and 6 months of age, respectively, to significantly improve the effect of interruption of mother-to-child transmission. 2, To further reduce mother-to-child transmission of HBV, HBV DNA > 2×106 IU/mL in the middle and late stages of immune-tolerant pregnancy, TDF, LdT or LAM can be given starting from the 24th-28th weeks of pregnancy on the basis of full communication of informed consent, and it is recommended to stop the drug 1-3 months after delivery, and breastfeeding can be done after stopping the drug. 3. In patients with hepatitis B exacerbation during pregnancy, mild elevation of ALT can be closely observed, and in those with more severe liver lesions, TDF or LdT antiviral therapy can be used after full communication with the patient and weighing the pros and cons.